249.38MMarket Cap-7950P/E (TTM)
5.200High4.740Low1.40MVolume4.990Open4.980Pre Close6.80MTurnover3.18%Turnover RatioLossP/E (Static)52.28MShares6.14052wk High8.98P/B209.55MFloat Cap1.08052wk Low--Dividend TTM43.93MShs Float69.570Historical High--Div YieldTTM9.23%Amplitude1.080Historical Low4.863Avg Price1Lot Size
G1 Therapeutics Stock Forum
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Liquidia(LQDA.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$MorphoSys(MOR.US)$ Phase 3
$Immunocore(IMCR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$Capricor Therapeutics(CAPR.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3...
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US)$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US)$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US)$
• Ph 3 data (PATHFND...
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$ $Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...
No comment yet